Anti-DLL3 antibody drug conjugates

Patent metadata

Field	Value
Publication number	US-9480757-B2
Application number	US-201615135542-A
Country	US
Kind code	B2
Filing date	Apr 21, 2016
Priority date	Feb 24, 2012
Publication date	Nov 1, 2016
Grant date	Nov 1, 2016

Abstract

Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.

First claim

The invention claimed is:

1. An antibody drug conjugate of the formula M-[L-D]n, or a pharmaceutically acceptable salt thereof, wherein:
M comprises an anti-DLL3 antibody that specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4, wherein M is an internalizing antibody;
L comprises a linker;
D comprises a cytotoxic agent; and
n is an integer from 1 to 20.

2. The antibody drug conjugate of claim 1 comprising the structure:

wherein:
CBA is a cell binding agent, which is the anti-DLL3 antibody M;
A, L 1 , and L 2 are components of the linker L;
A is a connecting group connecting L 1 to the cell binding agent (CBA);
L 1 is optionally a cleavable linker;
L 2 is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and
wherein the linker L is attached to the cytotoxic agent at the position of the asterisk (*).

3. The antibody drug conjugate of claim 2 , wherein the moiety:

comprises the structure:

wherein the wavy line indicates the point of attachment of the structure directly to A or to a remaining portion of L1 that is further connected to A.

4. The antibody drug conjugate of claim 2 , wherein the linker comprises a cleavable linker.

5. The antibody drug conjugate of claim 4 , wherein the cleavable linker comprises a dipeptide.

6. The antibody drug conjugate of claim 5 , wherein the dipeptide is Phe-Lys, Val-Ala, Val-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp-Cit.

7. The antibody drug conjugate of claim 6 , wherein the dipeptide is Val-Ala.

8. The antibody drug conjugate of claim 1 , wherein the anti-DLL3 antibody specifically binds to an epitope comprising amino acids G203, R205 and P206 (SEQ ID NO: 10).

9. The antibody drug conjugate of claim 1 , wherein the anti-DLL3 antibody is selected from the group consisting of a monoclonal antibody, chimeric antibody, CDR-grafted antibody, humanized antibody, human antibody, primatized antibody, multispecific antibody, bispecific antibody, monovalent antibody, multivalent antibody, anti-idiotypic antibody, diabody, Fab fragment, F(ab′) 2 fragment, Fv fragment, and ScFv fragment; or an immunoreactive fragment thereof.

10. The antibody drug conjugate of claim 1 , wherein the anti-DLL3 antibody is a chimeric antibody, a CDR-grafted antibody, humanized antibody, or human antibody.

11. The antibody drug conjugate of claim 1 , wherein the anti-DLL3 antibody competes for binding to a human DLL3 protein with an antibody comprising a light chain variable region set forth as SEQ ID NO: 84 and a heavy chain variable region set forth as SEQ ID NO: 85.

12. The antibody drug conjugate of claim 11 , wherein the anti-DLL3 antibody comprises three CDRs of a light chain variable region set forth as SEQ ID NO: 84 and three CDRs of a heavy chain variable region set forth as SEQ ID NO: 85.

13. The antibody drug conjugate of claim 11 , wherein the anti-DLL3 antibody comprises residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 31-35 of SEQ ID NO: 85 for CDR-H1, residues 50-65 of SEQ ID NO: 85 for CDR-H2 and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Kabat.

14. The antibody drug conjugate of claim 11 , wherein the anti-DLL3 antibody comprises residues 23-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 26-32 of SEQ ID NO: 85 for CDR-H1, residues 50-58 of SEQ ID NO: 85 for CDR-H2 and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Chothia.

15. The antibody drug conjugate of claim 11 , wherein the anti-DLL3 antibody comprises residues 30-36 of SEQ ID NO: 84 for CDR-L1, residues 46-55 of SEQ ID NO: 84 for CDR-L2, residues 89-96 of SEQ ID NO: 84 for CDR-L3, residues 30-35 of SEQ ID NO: 85 for CDR-H1, residues 47-58 of SEQ ID NO: 85 for CDR-H2 and residues 93-101 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to MacCallum.

16. The antibody drug conjugate of claim 11 , wherein the anti-DLL3 antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213.

17. The antibody drug conjugate of claim 1 , wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD), an auristatin, a maytansinoid, a calicheamicin, a duocarmycin derivative, a dolastatin, or an amanatin.

18. The antibody drug conjugate of claim 17 , wherein the cytotoxic agent comprises an auristatin.

19. The antibody drug conjugate of claim 17 , wherein the cytotoxic agent comprises a maytansinoid.

20. The antibody drug conjugate of claim 17 , wherein the cytotoxic agent comprises a calicheacmicin.

21. The antibody drug conjugate of claim 17 , wherein the cytotoxic agent comprises a pyrrolobenzodiazepine (PBD).

22. The antibody drug conjugate of claim 21 , wherein the pyrrolobenzodiazepine (PBD) comprises the formula AC:

wherein:
the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond;
R 2 is selected from H, OH, ═O, ═CH 2 , CN, R, OR, ═CH—R D , ═C(R D ) 2 , O—SO 2 —R, CO 2 R, COR, and halo, where R D is selected from R, CO 2 R, COR, CHO, CO 2 H, and halo;
R 6 and R 9 are each independently selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR′, NO 2 , Me 3 Sn and halo;
R 10 is the linker L connected to the anti-DLL3 antibody;
Q is selected from O, S and NH;
R 11 is either H, or R or, where Q is O, SO 3 M, where M is a metal cation;
R and R′ are each independently selected from optionally substituted C 1-12 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups, and optionally in relation to the group NRR′, R and R′ together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring;
X is selected from O, S, and N(H);
R 2″ , R 6″ , R 7″ , R 9″ , and X″ are as defined according to R 2 , R 6 , R 7 , R 9 , and X, respectively; and
R″ is a C 3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted.

23. The antibody drug conjugate of claim 22 , wherein R 2 is R, wherein R is a C 5-20 aryl group.

24. The antibody drug conjugate of claim 22 , wherein R 6 and R 9 are H.

25. The antibody drug conjugate of claim 22 , wherein R 7 is OR.

26. The antibody drug conjugate of claim 25 , wher

Assignees

• Stemcentrx Inc
• Abbvie Stemcentrx Llc

Inventors

• Stull Robert A
• Saunders Laura
• Dylla Scott J
• Foord Orit
• Liu David
• Torgov Michael
• Shao Hui

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title

• A61K47/6825

  Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin · CPC title